The results of Sino-US pharmaceutical cooperation have been approved for first-line treatment of lung cancer patients

The State Drug Administration on the 3rd approved the innovative drug PD-1 inhibitor Dabershu, combined chemotherapy for EGFR gene mutation and APK negative, non-surgical removal of local late stage or metastasis non-squamous non-small cell lung cancer patients first-line treatment.
, lung cancer incidence is the second highest in the world and the first mortality rate.
according to histological type, lung cancer is divided into small cell lung cancer and non-small cell lung cancer, of which non-small cell lung cancer accounts for about 80% to 85%.
about 70% of non-small cell lung cancer patients in China are non-squamous non-small cell lung cancer, and nearly half of these patients are not suitable for targeted treatment, treatment methods are limited.
reporter learned that immunotherapy is a hot research field in recent years.
Daboshu? A home-grown PD-1 inhibitor developed by Xinda Bio and Lilly usa, it was approved in China in December 2018 for the treatment of relapsed/refractic classic Hodgkin's lymphoma.
the drug also entered the National Health Insurance Directory in November 2019.
Xinda Bio said the new adaptation was approved based on a double-blind, randomized phase III clinical study led by Professor Zhang Zhang of Sun Yat-sen University's Cancer Prevention and Control Center. Combined chemotherapy was compared to chemotherapy alone for first-line treatment of advanced or reocctic non-squamous non-small cell lung cancer without EGFR sensitive mutations or APK gene rearmaging.
results show that compared to chemotherapy alone, Dabershu? Combined chemotherapy significantly prolonged progress-free survival.
the current research and development team is expanding Dabershu? More than 20 worldwide studies on Daboshu? clinical studies.
In addition to the two adaptive disorders that have been approved for the market, Dabshu's first- and second-line applications for the treatment of squamous non-small cell lung cancer, as well as the first-line treatment of liver cancer, have been accepted by the State Drug Administration.
clinical studies in the fields of esophageal cancer, colorectal cancer, stomach cancer, bile tube cancer, cervical cancer, lymphoma and melanoma are also ongoing.
it is worth mentioning that, in order to enable more patients to afford high-quality biological drugs, Thyda Bio and the China Cancer Foundation set up a health public welfare poverty alleviation program to provide eligible low-income patients with free Daboshu? so that poor patients can also receive advanced treatments.
in order to effectively reduce the financial burden on patients, in January this year, Thyda Bio responded to the call of the Beijing KangMer Foundation and has participated in the "Shuxin-Oncology Immunotherapy Patient Relief Project".
China News Network Source: China News Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here